Femasys (NASDAQ:FEMY) Posts Earnings Results, Beats Expectations By $0.02 EPS

Femasys (NASDAQ:FEMY) posted its quarterly earnings data on Thursday. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02, Zacks reports. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%.

Femasys Trading Down 13.5 %

NASDAQ:FEMY opened at $1.32 on Thursday. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. Femasys has a 52-week low of $0.86 and a 52-week high of $1.84. The stock’s 50 day moving average price is $1.40 and its 200 day moving average price is $1.22. The company has a market capitalization of $30.11 million, a PE ratio of -1.61 and a beta of -2.85.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their price target on Femasys from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, March 19th.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.